Kawarada Yuki, Inoue Yasumichi, Kawasaki Fumihiro, Fukuura Keishi, Sato Koichi, Tanaka Takahito, Itoh Yuka, Hayashi Hidetoshi
Department of Cell Signaling, Graduate School of Pharmaceutical Sciences, Nagoya City University, 467-8603 Nagoya, Japan.
Department of Innovative Therapeutics Sciences, Cooperative major in Nanopharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Nagoya City University, 467-8603 Nagoya, Japan.
Sci Rep. 2016 Oct 19;6:35483. doi: 10.1038/srep35483.
Transforming growth factor β (TGF-β) signaling facilitates tumor development during the advanced stages of tumorigenesis, but induces cell-cycle arrest for tumor suppression during the early stages. However, the mechanism of functional switching of TGF-β is still unknown, and it is unclear whether inhibition of TGF-β signaling results amelioration or exacerbation of cancers. Here we show that the tumor suppressor p53 cooperates with Smad proteins, which are TGF-β signal transducers, to selectively activate plasminogen activator inhibitor type-1 (PAI-1) transcription. p53 forms a complex with Smad2/3 in the PAI-1 promoter to recruit histone acetyltransferase CREB-binding protein (CBP) and enhance histone H3 acetylation, resulting in transcriptional activation of the PAI-1 gene. Importantly, p53 is required for TGF-β-induced cytostasis and PAI-1 is involved in the cytostatic activity of TGF-β in several cell lines. Our results suggest that p53 enhances TGF-β-induced cytostatic effects by activating PAI-1 transcription, and the functional switching of TGF-β is partially caused by p53 mutation or p53 inactivation during cancer progression. It is expected that these findings will contribute to optimization of TGF-β-targeting therapies for cancer.
转化生长因子β(TGF-β)信号传导在肿瘤发生的晚期促进肿瘤发展,但在早期诱导细胞周期停滞以抑制肿瘤。然而,TGF-β功能转换的机制仍然未知,并且尚不清楚抑制TGF-β信号传导是否会导致癌症改善或恶化。在这里,我们表明肿瘤抑制因子p53与作为TGF-β信号转导分子的Smad蛋白协同作用,以选择性激活1型纤溶酶原激活物抑制剂(PAI-1)转录。p53在PAI-1启动子中与Smad2/3形成复合物,以募集组蛋白乙酰转移酶CREB结合蛋白(CBP)并增强组蛋白H3乙酰化,从而导致PAI-1基因的转录激活。重要的是,p53是TGF-β诱导的细胞停滞所必需的,并且PAI-1在几种细胞系中参与TGF-β的细胞停滞活性。我们的结果表明,p53通过激活PAI-1转录增强TGF-β诱导的细胞停滞作用,并且TGF-β的功能转换部分是由癌症进展过程中的p53突变或p53失活引起的。预计这些发现将有助于优化针对癌症的TGF-β靶向治疗。